GlassScriptPhysician profile
Afshid Roozrokh
NPI 1205162823
$2,560.30
in general payments reported to CMS, 2019-2025
25 companies · $710 in 2025
The $710 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $441 · 2023: $484 · 2024: $264 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.77 | 2021-2025 | Tezspire, Fasenra, Flumist Quadrivalent |
| Abbvie INC. | $266.11 | 2021-2025 | |
| Pfizer INC. | $257.31 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $217.19 | 2023-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Cranial Technologies, INC | $190.50 | 2021-2025 | Doc Band |
| Amgen INC. | $181.34 | 2021-2025 | Tezspire |
| Mayne Pharma Commercial LLC | $176.10 | 2023-2025 | |
| Sanofi Pasteur INC. | $139.25 | 2021-2024 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Alk-Abello, INC | $86.51 | 2022-2025 | Neffy, Odactra, Ragwitek |
| Abbott Laboratories | $82.18 | 2023-2025 | Id Now Instrument |
| Novartis Pharmaceuticals Corporation | $63.29 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $55.90 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $48.75 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $39.19 | 2025 | Orladeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $36.98 | 2021-2025 | Immunocap |
| Seqirus USA INC | $35.99 | 2022-2025 | Fluad, Flucelvax |
| Cognoa, INC. | $31.52 | 2021 | |
| Angiodynamics, INC. | $29.06 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.02 | 2025 | Alvesco |
| Regeneron Healthcare Solutions, INC. | $22.65 | 2023 | Dupixent |
| Tris Pharma INC | $19.75 | 2021 | |
| Neos Therapeutics, LP | $19.33 | 2025 | Adzenys Xr-Odt |
| Genzyme Corporation | $14.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshid Roozrokh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.